INBX
Income statement / Annual
Last year (2023), Inhibrx Biosciences, Inc.'s total revenue was $1.80 M,
a decrease of 17.36% from the previous year.
In 2023, Inhibrx Biosciences, Inc.'s net income was -$241.36 M.
See Inhibrx Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.80 M
|
$2.18 M
|
$7.13 M
|
$12.81 M
|
$9.09 M
|
$7.50 M
|
$7.95 M
|
$6.67 M
|
| Cost of Revenue |
$1.19 M |
$2.85 M |
$2.69 M |
$73.50 M |
$47.91 M |
$33.45 M |
$25.51 M |
$16.99 M |
| Gross Profit |
$609,000.00 |
-$668,000.00 |
$4.44 M |
-$60.69 M |
-$38.81 M |
-$25.95 M |
-$17.56 M |
-$10.33 M |
| Gross Profit Ratio |
0.34 |
-0.31 |
0.62 |
-4.74 |
-4.27 |
-3.46 |
-2.21 |
-1.55 |
| Research and Development
Expenses |
$191.64 M
|
$110.19 M
|
$71.44 M
|
$73.50 M
|
$47.91 M
|
$33.45 M
|
$25.51 M
|
$16.99 M
|
| General & Administrative
Expenses |
$29.38 M
|
$21.12 M
|
$12.36 M
|
$6.84 M
|
$9.02 M
|
$4.65 M
|
$2.61 M
|
$1.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$253,000.00
|
| Selling, General &
Administrative Expenses |
$29.38 M
|
$21.12 M
|
$12.36 M
|
$6.84 M
|
$9.02 M
|
$4.65 M
|
$2.61 M
|
$1.57 M
|
| Other Expenses |
$0.00 |
-$14,000.00 |
-$106,000.00 |
-$80,000.00 |
-$4.12 M |
$68,000.00 |
$24,000.00 |
$0.00 |
| Operating Expenses |
$219.83 M |
$131.30 M |
$83.69 M |
$80.25 M |
$52.81 M |
$37.01 M |
$27.68 M |
$18.56 M |
| Cost And Expenses |
$221.02 M |
$131.30 M |
$83.69 M |
$80.25 M |
$52.81 M |
$37.01 M |
$27.68 M |
$18.81 M |
| Interest Income |
$11.92 M |
$16.11 M |
$5.22 M |
$10.82 M |
$5.72 M |
$0.00 |
$0.00 |
$759,000.00 |
| Interest Expense |
$31.84 M |
$16.11 M |
$5.22 M |
$10.82 M |
$5.72 M |
$1.48 M |
$2.13 M |
$0.00 |
| Depreciation &
Amortization |
$1.19 M
|
$1.23 M
|
$2.69 M
|
$2.39 M
|
$2.52 M
|
$676,000.00
|
$399,000.00
|
$253,000.00
|
| EBITDA |
-$206.69 M
|
-$125.82 M
|
-$76.56 M
|
-$67.44 M
|
-$42.60 M
|
-$28.77 M
|
-$19.31 M
|
-$11.89 M
|
| EBITDA Ratio |
-114.83 |
-59.28 |
-10.75 |
-5.27 |
-4.69 |
-3.84 |
-2.43 |
-1.78 |
| Operating Income Ratio
|
-121.79
|
-59.28
|
-10.75
|
-5.27
|
-4.81
|
-3.94
|
-2.48
|
-1.82
|
| Total Other
Income/Expenses Net |
-$20.50 M
|
-$29.90 M
|
-$5.20 M
|
-$8.19 M
|
-$6.79 M
|
-$1.41 M
|
-$2.10 M
|
-$739,000.00
|
| Income Before Tax |
-$239.72 M |
-$145.22 M |
-$81.77 M |
-$75.63 M |
-$50.50 M |
-$30.93 M |
-$21.83 M |
-$12.89 M |
| Income Before Tax Ratio
|
-133.18
|
-66.68
|
-11.48
|
-5.91
|
-5.55
|
-4.12
|
-2.75
|
-1.93
|
| Income Tax Expense |
$3,000.00 |
$3,000.00 |
$2,000.00 |
$3,000.00 |
$898,000.00 |
$96,000.00 |
$250,000.00 |
-$4.62 M |
| Net Income |
-$241.36 M |
-$145.23 M |
-$81.77 M |
-$75.64 M |
-$51.40 M |
-$31.16 M |
-$19.44 M |
-$8.27 M |
| Net Income Ratio |
-134.09 |
-66.68 |
-11.48 |
-5.91 |
-5.65 |
-4.16 |
-2.45 |
-1.24 |
| EPS |
-5.12 |
-3.62 |
-2.15 |
-2.99 |
-1.41 |
-1.15 |
-0.68 |
-0.23 |
| EPS Diluted |
-5.12 |
-3.62 |
-2.15 |
-2.99 |
-1.41 |
-1.15 |
-0.68 |
-0.23 |
| Weighted Average Shares
Out |
$47.13 M
|
$40.11 M
|
$38.01 M
|
$25.26 M
|
$36.55 M
|
$27.08 M
|
$28.79 M
|
$36.55 M
|
| Weighted Average Shares
Out Diluted |
$47.13 M
|
$40.11 M
|
$38.01 M
|
$25.26 M
|
$36.55 M
|
$27.08 M
|
$28.79 M
|
$36.55 M
|
| Link |
|
|
|
|
|
|
|
|
